miR-29b inhibits non-small cell lung cancer progression by targeting STRN4

• DOI: 10.1007/s13577-019-00305-w
• Publication Date: 2019-12-07T14:02:36Z
• Authors: Yuping Xie; Fen Zhao; Ping Zhang; Ping Duan; Yangmei Shen
• Keywords: 0301 basic medicine; MicroRNAs; 03 medical and health sciences; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Calmodulin-Binding Proteins; 3. Good health

Non-small cell lung cancer (NSCLC) is a malignant tumor with a high fatality, low overall cure, and survival rates worldwide. When only palliative therapy is available, the disease leads to malignant proliferation. Previous studies showed miR-29b serves as an NSCLC suppressor by inhibiting cells proliferation, migration, and invasion. However, the mechanism underlying NSCLC progression remains elusive. In this study, we identified Striatin 4 (STRN4), a target of miR-29b, which serves as a pro-oncogenic protein by promoting cells proliferation, migration, and invasion in NSCLC. Besides, the STRN4 was highly expressed in NSCLC and negatively regulated by miR-29b. Down-regulation of STRN4 inhibits NSCLC cells proliferation, migration, invasion, and promotes apoptosis in vitro, whereas overexpression-induced enhanced cell migration and invasion could be reverved by miR-29b. Notably, overexpression of miR-29b and down-regulation of STRN4 by shRNA suppressed cellular proliferation and delayed tumor progression in vivo. Together, these findings identify a miR-29b/STRN4 regulatory pathway in NSCLC progression, which may provide a new sight for the treatment of NSCLC.